Ed Arce
Stock Analyst at WestPark Capital
(3.15)
# 181
Out of 5,182 analysts
353
Total ratings
47.89%
Success rate
11.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLPH Talphera | Initiates: Buy | $3 | $0.90 | +231.97% | 7 | Apr 30, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $15.34 | +82.53% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $42.60 | -29.58% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.09 | +12,010.09% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $7.94 | +844.58% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $9.22 | +550.76% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.16 | +546.55% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.37 | +142.09% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.09 | - | 17 | Apr 2, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.44 | +986.96% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $29.74 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.09 | +11,383.25% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.22 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.71 | +315.05% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $107.16 | -32.81% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $510.04 | -20.59% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.78 | -18.88% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $26.12 | +263.71% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.34 | +15.21% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $38.73 | +23.93% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.23 | -14.64% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $36.19 | -30.92% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.61 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.08 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $31.33 | -77.66% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $37.80 | -44.44% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.43 | - | 2 | Feb 15, 2017 |
Talphera
Apr 30, 2026
Initiates: Buy
Price Target: $3
Current: $0.90
Upside: +231.97%
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $15.34
Upside: +82.53%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $42.60
Upside: -29.58%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.09
Upside: +12,010.09%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $7.94
Upside: +844.58%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $9.22
Upside: +550.76%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.16
Upside: +546.55%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.37
Upside: +142.09%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.09
Upside: -
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.44
Upside: +986.96%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $29.74
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.09
Upside: +11,383.25%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $7.71
Upside: +315.05%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $107.16
Upside: -32.81%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $510.04
Upside: -20.59%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.78
Upside: -18.88%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $26.12
Upside: +263.71%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.34
Upside: +15.21%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $38.73
Upside: +23.93%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.23
Upside: -14.64%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $36.19
Upside: -30.92%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.61
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.08
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $31.33
Upside: -77.66%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $37.80
Upside: -44.44%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.43
Upside: -